Similarly, the relationship between putative glioblastoma mutational group, single-cell composition, and transitions between primary and recurrent tumors following different therapies will require further investigation to define NF1-specific cellular mechanisms underlying targeted therapy resistance, and analysis of matched primary/recurrent pairs will be critical to understand the relationship between treatment selection and tumor evolution. The gene discussed is NF1; the disease is neoplasm.